Laddar...
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF). The mechanisms by which SGLT2 inhibitors reduce such risk are likely to be independent of diabet...
Sparad:
| I publikationen: | Cardiovasc Diabetol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7722318/ https://ncbi.nlm.nih.gov/pubmed/33287812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01191-5 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|